EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Paxman AB (PXMBF) fair value: what the stock is really worth

We calculate from audited financials what Paxman AB is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN SE0009806284

PA Paxman AB logo Thin data Sep 13, 2026

Paxman AB

PXMBF · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.6100 · Strongly overvalued (−83%)
!Quality 20/100
!Expensive Growth (revenue 5y +32.0 %/yr)
!Loss-making · -3.3% net margin (TTM)
!Low debt · negative free cash flow
!Narrow moat 13/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$7.30 $2.80 Fair Value $0.6100 May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range $2.80 – $7.30 · fair‑value band $0.6000 – $0.6200 · the $3.50 price screens above the $0.6100 fair value. Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Paxman AB (publ), together with its subsidiaries, provides cryotherapy solutions in the United Kingdom, Europe, North and South America, Oceania, and Asia. The company offers Paxman scalp cooling system, a mechanized form of scalp cooling for the prevention of chemotherapy-induced alopecia.

Show more

Paxman AB (publ), together with its subsidiaries, provides cryotherapy solutions in the United Kingdom, Europe, North and South America, Oceania, and Asia. The company offers Paxman scalp cooling system, a mechanized form of scalp cooling for the prevention of chemotherapy-induced alopecia. It also engages in the development of a medical cryocompression device for the prevention of chemotherapy-induced peripheral neuropathy. The company was founded in 1996 and is based in Karlshamn, Sweden.

Stock analysis

Paxman AB (PXMBF) currently trades at $3.50, while our model-based Fair Value estimate is $0.6100, implying the stock looks roughly 473.7% overvalued today.

Show more

Valuation

Bull case: the Economic Profit group reads highest at a median of $5.80 per share, and 6 of the 6 models we run sit above the $3.50 price.

Bear case: the Earnings-Based group reads lowest at $5.80, and 0 of the 6 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.6000 (bear) to $0.6200 (bull), the price of $3.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Paxman AB reported revenue of 313M SEK in FY2025 versus 96.2M SEK in FY2021, a compound +34.3%/yr. Reported net income was −16.7M SEK in FY2025.

Key figures

Market cap $77.1M · P/E ratio 29.2 · P/S ratio 0.27 · EPS (TTM) $0.1200 · Net margin −5.3% · Return on equity −3.3% · Return on assets (EBIT) 4.5% · Revenue (TTM) $305M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades near its 52-week high, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 0% fair-value upside, at −83%, PXMBF screens richer than that median.

Fair Value models

Bear $0.6000 Fair Value $0.6100 Bull $0.6200
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then ($0.0845 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV $5.72 $5.80 $5.86 74
ROIC Compounder $5.72 $5.80 $5.86 72
EV/EBITDA $17.88 $22.14 $26.41 67
All 6 models by family
Earnings-Based
EPV $5.72 $5.80 $5.86 74
Multiples
EV/EBIT $7.40 $8.17 $8.95 66
EV/EBITDA $17.88 $22.14 $26.41 67
EV/Revenue $6.73 $7.44 $8.16 54
Asset-Based
NCAV (Graham) $8.68 $11.63 $17.36 54
Economic Profit
ROIC Compounder $5.72 $5.80 $5.86 72

Open the full fair value analysis →

Notify me when PXMBF reaches fair value

Put PXMBF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 20/100

Of which business quality 25 · Market factors (momentum, volatility) 56

Profitability 11
Margins and returns on capital today
Quality Growth 19
Are margins and returns improving?
Cashflow 9
Earnings quality: real cash, not paper profit
Fin. Strength 64
Balance sheet, leverage, solvency risk
Investment 28
Disciplined investing over empire-building
Low Volatility 100
Calm price path (market factor)
Momentum 40
Price trend over the last 3–12 months (market factor)
52W Momentum 33
Distance to the 52-week high (market factor)
Net Issuance 15
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+23.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.0%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−15.0% (2020) → 1.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PXMBF screens 474% overvalued. Compare with Abbott Laboratories, →

Compare Paxman AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $101.95 $74.79 −27%
Stryker Corporation SYK $275.56 $303.12 +10%
Medtronic plc MDT $90.96 $65.57 −28%
Boston Scientific Corporation BSX $42.98 $47.28 +10%
Edwards Lifesciences Corporation EW $84.37 $82.04 −3%
Siemens Healthineers AG SHL €38.23 €33.87 −11%
DexCom, Inc DXCM $83.03 $91.33 +10%
GE HealthCare Technologies Inc GEHC $63.93 $64.13 +0%
Koninklijke Philips N.V PHIA €21.14 €14.36 −32%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥162.73 ¥179.00 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Paxman AB · Fair Value
$0.6100 −474%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Paxman AB Fair Value". https://www.fairvalue-calculator.com/stock/PXMBF

Frequently asked questions

Is Paxman AB (PXMBF) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $0.6100 versus a price of $3.50, about −83% upside (overvalued).
What is the fair value of PXMBF?
Our model-based fair value for Paxman AB is $0.6100 (as of Sep 13, 2026), built from audited fundamentals. The current price: $3.50.
What is the quality score of PXMBF?
Paxman AB has a Quality Score of 20/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Paxman AB (PXMBF)?
Our model-based price target is the fair value of $0.6100 (as of Sep 13, 2026) from 6 valuation models. Cautious scenario $0.6000, optimistic scenario $0.6200. It is a calculation from audited fundamentals, not an analyst target.
What is the Paxman AB stock forecast for 2026?
Our models put fair value at $0.6100, about −83% upside versus a price of $3.50 (overvalued). Cautious scenario $0.6000, optimistic scenario $0.6200. The calculation is refreshed regularly with new filings.
What is the revenue of Paxman AB (PXMBF)?
Paxman AB reported trailing-twelve-month revenue of about $305M (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Paxman AB (PXMBF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Paxman AB it is $0.6100 per share (as of Sep 13, 2026), against a price of $3.50. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is Paxman AB stock overvalued or undervalued in 2026?
As of Sep 13, 2026, PXMBF trades above its calculated fair value: price $3.50, fair value $0.6100, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PXMBF?
No. The price is what the market pays today ($3.50); the fair value is what the company's own numbers justify ($0.6100). For Paxman AB the two are $2.89 per share apart. That gap is exactly why we show both numbers side by side.
How much is Paxman AB worth?
The market values Paxman AB at about $77.1M (market capitalisation, as of Sep 13, 2026). Per share that is $3.50; our models calculate a fair value of $0.6100 per share.
What do the bullish and bearish scenarios say about PXMBF?
Our models span a range for Paxman AB: cautious scenario $0.6000, base $0.6100, optimistic $0.6200 per share (as of Sep 13, 2026, price $3.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is PXMBF from its 52-week high?
Paxman AB trades at $3.50, about 0% below its 52-week high of $3.50 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6100 is for.
Which stocks are comparable to Paxman AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Paxman AB stock attractive at the current price?
The data as of Sep 13, 2026: price $3.50, calculated fair value $0.6100 (−83%), Quality Score 20/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PXMBF calculated?
We run Paxman AB through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.6100, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Paxman AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Paxman AB right now?
The price sits above even our optimistic bull case ($0.6200). The favourable scenario is already priced in. Weak quality (20/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band ($0.6000 to $0.6200), unusually little disagreement for a valuation.

Key figures of Paxman AB

How large is the market capitalisation of Paxman AB (PXMBF)?
The market capitalisation of Paxman AB is $77.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Paxman AB (PXMBF)?
The price-to-earnings ratio of Paxman AB is 29.2. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Paxman AB (PXMBF)?
The price-to-sales ratio of Paxman AB is 0.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Paxman AB (PXMBF)?
Earnings per share at Paxman AB are $0.1200 (price ÷ EPS = P/E 29.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Paxman AB (PXMBF)?
The net margin of Paxman AB is −5.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Paxman AB (PXMBF)?
The return on equity (ROE) of Paxman AB is −3.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Paxman AB (PXMBF)?
On an EBIT basis the return on assets of Paxman AB is 4.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Paxman AB (PXMBF)?
Revenue at Paxman AB is growing +30.7% versus a year earlier (3y avg +25.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Paxman AB (PXMBF)?
Earnings per share at Paxman AB are growing −78.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Paxman AB (PXMBF) generate?
The free cash flow of Paxman AB is −$8.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Paxman AB (PXMBF) hold?
Paxman AB holds more cash than debt, $108M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.